Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Eur J Pharmacol. 2011 Jul 3;668(1-2):299–304. doi: 10.1016/j.ejphar.2011.06.027

Figure 1. Effects of C3a receptor agonists and compound 48/80 on degranulation in human mast cells.

Figure 1

(A) LAD2 mast cells were stimulated with different concentrations of C3a, C3 desArg, C3aP, C3a receptor superagonist E7 and scrambled E7 (E7S) for 30 min and percent degranulation (β-hexosaminidase release) was determined. (B) LAD2 cells were stimulated with different concentrations of compound 48/80 and degranulation was determined. (C) CD34+-derived human mast cells were exposed to buffer (control), C3a (100 nM), E7 or E7S (1 µM) for 30 min and percent degranulation was determined. Data are mean ± S.E.M of 3 – 4 experiments. Statistical significance was tested using two way (A) or one way (B and C) ANOVA with Bonferroni’s post test. * indicates P<0.05